ZFIN ID: ZDB-FISH-150901-24040
Fish name: jh4Tg
Genotype: jh4Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by jh4Tg
Human Disease Conditions Citations
diabetes mellitus chemical ablation: pancreatic B cell, chemical treatment by environment: metronidazole Rocker et al., 2019
chemical treatment: metronidazole Carvalho et al., 2017
GENE EXPRESSION
Gene expression in jh4Tg
RNA expression
Expressed Gene Structure Conditions Figures
bglapl standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
ins control Fig. 5 from Carvalho et al., 2017
Fig. 6 with image from Manfroid et al., 2012
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
Fig. 6 with image from Manfroid et al., 2012
insb standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
insra standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
pth1r standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
runx2b standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
sp7 standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vdra standard conditions Fig. 5 from Carvalho et al., 2017
chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
Reporter gene expression
Expressed Gene Structure Conditions Figures
mCherry control Fig. 1 with image from Rocker et al., 2019
Fig. 1 with image from Nath et al., 2015
chemical treatment: metronidazole Fig. 1 with image from Rocker et al., 2019
Fig. 1 with image from Nath et al., 2015
PHENOTYPE
Phenotype in jh4Tg
Phenotype Conditions Figures
blood glucose increased amount, abnormal chemical treatment: metronidazole Fig. 1 from Carvalho et al., 2017
endocrine pancreas has normal numbers of parts of type insulin secreting cell, normal chemical treatment: metronidazole Fig. 6 with image from Manfroid et al., 2012
glucose homeostasis disrupted, abnormal chemical treatment: metronidazole Fig. 1 from Carvalho et al., 2017
motor neuron axon defasciculated, abnormal chemical ablation: pancreatic B cell, chemical treatment by environment: metronidazole Fig. 5 with image from Rocker et al., 2019
myelinating Schwann cell decreased amount, abnormal chemical ablation: pancreatic B cell, chemical treatment by environment: metronidazole Fig. 6 with image from Rocker et al., 2019
opercle decreased size, abnormal chemical treatment: metronidazole Fig. 2 from Carvalho et al., 2017
opercle bone mineralization decreased process quality, abnormal chemical treatment: metronidazole Fig. 2 from Carvalho et al., 2017
opercle bone mineralization decreased process quality, ameliorated chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 2 from Carvalho et al., 2017
opercle bone mineralization decreased process quality, ameliorated chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 2 from Carvalho et al., 2017
opercle bone mineralization decreased process quality, ameliorated chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 2 from Carvalho et al., 2017
opercle bone mineralization increased process quality, abnormal chemical treatment: cinacalcet Fig. 2 from Carvalho et al., 2017
opercle bone mineralization increased process quality, abnormal chemical treatment: paricalcitol Fig. 2 from Carvalho et al., 2017
opercle bone mineralization process quality, normal chemical treatment: vitamin D Fig. 2 from Carvalho et al., 2017
pancreatic B cell absent, abnormal chemical ablation: pancreatic B cell, chemical treatment by environment: metronidazole Fig. 1 with image from Rocker et al., 2019
pancreatic B cell mCherry expression absent, abnormal chemical ablation: pancreatic B cell, chemical treatment by environment: metronidazole Fig. 1 with image from Rocker et al., 2019
pancreatic B cell decreased amount, abnormal chemical treatment: metronidazole Fig. 1 with image from Nath et al., 2015
regenerating fin decreased size, abnormal amputation: caudal fin, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin decreased size, abnormal amputation: caudal fin, chemical treatment: vitamin D, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin increased variability of size, abnormal amputation: caudal fin, chemical treatment: vitamin D, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin size, ameliorated amputation: caudal fin, chemical treatment: cinacalcet, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin size, ameliorated amputation: caudal fin, chemical treatment: metronidazole, chemical treatment: paricalcitol Fig. 3 from Carvalho et al., 2017
regenerating fin size, normal amputation: caudal fin, chemical treatment: vitamin D Fig. 3 from Carvalho et al., 2017
regenerating fin size, normal amputation: caudal fin, chemical treatment: cinacalcet Fig. 3 from Carvalho et al., 2017
regenerating fin size, normal amputation: caudal fin, chemical treatment: paricalcitol Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization decreased occurrence, abnormal amputation: caudal fin, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization decreased occurrence, abnormal amputation: caudal fin, chemical treatment: vitamin D, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization occurrence, ameliorated amputation: caudal fin, chemical treatment: vitamin D, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization occurrence, ameliorated amputation: caudal fin, chemical treatment: metronidazole, chemical treatment: paricalcitol Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization occurrence, ameliorated amputation: caudal fin, chemical treatment: cinacalcet, chemical treatment: metronidazole Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization occurrence, normal amputation: caudal fin, chemical treatment: vitamin D Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization occurrence, normal amputation: caudal fin, chemical treatment: cinacalcet Fig. 3 from Carvalho et al., 2017
regenerating fin bone mineralization occurrence, normal amputation: caudal fin, chemical treatment: paricalcitol Fig. 3 from Carvalho et al., 2017
regenerating fin caudal fin principal ray decreased thickness, abnormal amputation: caudal fin, chemical treatment: vitamin D, chemical treatment: metronidazole Fig. 4 from Carvalho et al., 2017
regenerating fin caudal fin principal ray decreased thickness, abnormal amputation: caudal fin, chemical treatment: metronidazole Fig. 4 from Carvalho et al., 2017
regenerating fin caudal fin principal ray thickness, ameliorated amputation: caudal fin, chemical treatment: cinacalcet, chemical treatment: metronidazole Fig. 4 from Carvalho et al., 2017
regenerating fin caudal fin principal ray thickness, ameliorated amputation: caudal fin, chemical treatment: metronidazole, chemical treatment: paricalcitol Fig. 4 from Carvalho et al., 2017
regenerating fin caudal fin principal ray thickness, normal amputation: caudal fin, chemical treatment: cinacalcet Fig. 4 from Carvalho et al., 2017
regenerating fin caudal fin principal ray thickness, normal amputation: caudal fin, chemical treatment: paricalcitol Fig. 4 from Carvalho et al., 2017
regenerating fin caudal fin principal ray thickness, normal amputation: caudal fin, chemical treatment: vitamin D Fig. 4 from Carvalho et al., 2017
type B pancreatic cell differentiation process quality, normal chemical treatment: metronidazole Fig. 6 with image from Manfroid et al., 2012
vertebral column sp7 expression amount, ameliorated chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column sp7 expression amount, ameliorated chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column insra expression amount, ameliorated chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column insb expression amount, ameliorated chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 5 from Carvalho et al., 2017
vertebral column bglapl expression amount, ameliorated chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column bglapl expression amount, ameliorated chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column ins expression amount, ameliorated chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 5 from Carvalho et al., 2017
vertebral column sp7 expression decreased amount, abnormal chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 5 from Carvalho et al., 2017
vertebral column sp7 expression decreased amount, abnormal chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column insb expression decreased amount, abnormal chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column ins expression decreased amount, abnormal chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column insra expression decreased amount, abnormal chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column bglapl expression decreased amount, abnormal chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 5 from Carvalho et al., 2017
vertebral column bglapl expression decreased amount, abnormal chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column pth1r expression decreased amount, abnormal chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 5 from Carvalho et al., 2017
vertebral column pth1r expression decreased amount, abnormal chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column pth1r expression decreased amount, abnormal chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column insra expression decreased amount, abnormal chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column insra expression decreased amount, abnormal chemical treatment: metronidazole, chemical treatment: vitamin D Fig. 5 from Carvalho et al., 2017
vertebral column runx2b expression increased amount, abnormal chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column runx2b expression increased amount, abnormal chemical treatment: paricalcitol Fig. 5 from Carvalho et al., 2017
vertebral column sp7 expression increased amount, abnormal chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column runx2b expression increased amount, abnormal chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column runx2b expression increased amount, abnormal chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column vdra expression increased amount, abnormal chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column insb expression increased amount, abnormal chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column insra expression increased amount, abnormal chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column insb expression increased amount, abnormal chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column ins expression increased amount, abnormal chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column insb expression increased amount, abnormal chemical treatment: paricalcitol Fig. 5 from Carvalho et al., 2017
vertebral column ins expression increased amount, abnormal chemical treatment: paricalcitol Fig. 5 from Carvalho et al., 2017
vertebral column ins expression increased amount, abnormal chemical treatment: paricalcitol, chemical treatment: metronidazole Fig. 5 from Carvalho et al., 2017
vertebral column ins expression increased amount, abnormal chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column vdra expression increased amount, abnormal chemical treatment: metronidazole, chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017
vertebral column insb expression increased amount, abnormal chemical treatment: cinacalcet Fig. 5 from Carvalho et al., 2017

CITATIONS  (10)